Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Kyowa Kirin Gains Rights to NHE3 Inhibitor in Japan
November 29, 2017
- Stefan Woxström Tapped as New AZ Japan President Effective Jan. 2018
November 28, 2017
- EA Pharma Files Constipation Drug AJG555 in Japan
November 28, 2017
- Santen Files Omidenepag Isopropyl for Glaucoma, Ocular Hypertension in Japan
November 28, 2017
- Tagrisso Filed for 1st-Line EGFR-Mutated NSCLC in Japan: AZ
November 28, 2017
- ASKA to Invest Management Resources Actively in New Drugs, Not Generics
November 27, 2017
- Takeda Spin-Off Chordia Concludes Investment Contract with Takeda, Venture Capitals
November 27, 2017
- Masamichi Terabatake to Be Appointed President of JT, Wants to “Steadily Invest” in Pharma Business
November 24, 2017
- Fuji Pharma Might Review Development Plans for Nesp Biosimilar Expecting Fierce Competition
November 24, 2017
- Daiichi Sankyo Begins PII Study of DS-8201 for Gastric Cancer in Japan, South Korea
November 22, 2017
- Mochida to Market Janssen’s Anticancer Agent Doxil in Japan
November 22, 2017
- Canalia Grabs GPs’ Attention in September: Anterio Ranking
November 21, 2017
- Pfizer Begins Submitting Applications for Biosimilars, Could Be First Major New Drug Maker to Enter Japanese Market
November 21, 2017
- Sales of 4 Top Wholesalers Down 0.2% in April-Sept. Following Decline in Demand for Hep C Drugs
November 21, 2017
- M3 Enters Regenerative Medicine Field, Investing 200 Million Yen in Biotech Firm
November 21, 2017
- Eisai’s Fycompa Available again in Germany from December following Reimbursement Price Settlement with Regulator
November 21, 2017
- 1st Patient Enrolled in PII/III for Healios’ Sakigake-Designated Stem Cell Therapy
November 17, 2017
- Maruho Exec Requests Discussions on Proper Use of Heparinoid Agents Based on “Appropriate Data,” Calls for Detailed Analysis of NDB
November 17, 2017
- Adcetris Gets European Panel Backing for CTCL: Takeda
November 16, 2017
- Transfer of LLPs from Chugai “Our Ticket to Admission” into Pharma Business: Taiyo Pharma COO
November 16, 2017
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…